

Poor immune response in many doublevaccinated blood cancer patients

October 21 2021



Credit: Unsplash/CC0 Public Domain

More than half of double-vaccinated blood cancer patients have been left with little protection against COVID-19, new research has found.



Data from the SOAP-02 trial, published today in a <u>letter</u> to *Cancer Cell*, examines the level of immune protection following the delayed Pfizer vaccine boost in 159 participants, 128 of whom were <u>cancer</u> patients. Although administering the second dose increased rates of seroconversion (development of antibodies to SARS-CoV-2) in blood cancer patients from

Citation: Poor immune response in many double- vaccinated blood cancer patients (2021, October 21) retrieved 27 April 2024 from <u>https://medicalxpress.com/news/2021-10-poor-immune-response-double-vaccinated.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.